| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vitro |
Ciwujianoside B at concentrations of 1 and 10 µM significantly increased the total dendrite length in primary cultured mouse cortical neurons after 4 days of treatment. This effect was assessed by immunostaining for the dendritic marker microtubule-associated protein 2 (MAP2).[1]
|
|---|---|
| ln Vivo |
Oral administration of Ciwujianoside B (0.5 mg/kg/day for 17 days) significantly enhanced object recognition memory in normal male ddY mice. The test was performed with a 72-hour interval between training and test sessions. The treatment did not alter spontaneous locomotor activity or body weight in the mice.[1]
|
| Cell Assay |
Primary Cortical Neuron Dendrite Extension Assay: Cortical neurons were dissected from ddY mouse embryos at 14 days of gestation and cultured in neurobasal medium supplemented with B-27, D-glucose, and L-glutamine on poly-D-lysine coated chamber slides. After 3 days in culture, the neurons were treated with fresh medium containing Ciwujianoside B (1 and 10 µM) or vehicle (water) for 4 days. Subsequently, cells were fixed with 4% paraformaldehyde and immunostained using a primary antibody against MAP2 and an Alexa Fluor 568-conjugated secondary antibody. Nuclei were counterstained with DAPI. Fluorescence images were captured, and the total length of MAP2-positive dendrites (excluding cell bodies) was measured automatically using image analysis software. The sum of dendrite lengths was normalized to the number of MAP2-positive neurons.[1]
|
| Animal Protocol |
1. Memory Enhancement Study: Male ddY mice (8 weeks old) were orally administered Ciwujianoside B (0.5 mg/kg/day), suspended in distilled water, or vehicle once daily for 17 consecutive days. On day 14 of administration, locomotor activity was assessed in an open-field box for 10 minutes, and the training session of the object recognition test (ORT) was conducted. The test session of the ORT was performed after a 72-hour interval (on day 17). Body weight was monitored throughout the study period.[1]
2. Pharmacokinetic/Tissue Distribution Study: To detect compounds that penetrate the brain, a single high oral dose (5 g/kg) of the Eleutherococcus senticosus leaf water extract (containing Ciwujianoside B) was administered to female ddY mice (6 weeks old). At 3, 6, and 12 hours post-administration, mice were euthanized. Blood was collected, and plasma was obtained by centrifugation. The brain cortex was dissected after saline perfusion. Plasma and cortical tissue samples were processed (extracted with methanol, dried, and reconstituted) for subsequent LC-MS/MS analysis to detect Ciwujianoside B and other compounds.[1] |
| ADME/Pharmacokinetics |
Following a single oral administration of a high dose (5 g/kg) of Acanthopanax senticosus leaf aqueous extract, eleutheroside B (molecular weight 1189.35) was detected in the plasma and cerebral cortex of mice. The compound was detected in plasma at 3, 6, and 12 hours after administration, and in the cerebral cortex at 6 hours. This indicates that eleutheroside B can be absorbed into the systemic circulation and cross the blood-brain barrier (BBB). [1]
|
| References |
|
| Additional Infomation |
It has been reported that eleutheroside YM10 exists in Acanthopanax senticosus, and there are related data reports.
1. Eleutheroside B is a triterpenoid saponin isolated from Acanthopanax senticosus leaves. 2. Together with eleutheroside C3 and eleutheroside M, it has been identified as an active ingredient in the leaf extract, which has the effect of enhancing memory, can penetrate the blood-brain barrier and promote the growth of neuronal dendrites. [1] 3. Studies have shown that the memory-enhancing effect of eleutheroside B (and leaf extract) may be related to its ability to promote the extension of cortical neuronal dendrites. [1] 4. The content of eleutheroside B in the leaf extract is estimated to be about 0.1%, which provides a basis for the dose selection in the efficacy study of the pure compound (0.5). (mg/kg/day, equivalent to 0.1% of the effective extract dose of 500 mg/kg/day) [1] |
| Molecular Formula |
C58H92O25
|
|---|---|
| Molecular Weight |
1189.33608
|
| Exact Mass |
1186.613
|
| CAS # |
114902-16-8
|
| PubChem CID |
195123
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.627
|
| LogP |
7.67
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
25
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
83
|
| Complexity |
2350
|
| Defined Atom Stereocenter Count |
32
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@H]([C@@H]([C@H]2O)O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)[C@]45CCC(=C)C[C@H]4C6=CC[C@@H]7[C@]8(CC[C@@H](C([C@@H]8CC[C@]7([C@@]6(CC5)C)C)(C)C)O[C@H]9[C@@H]([C@H]([C@H](CO9)O)O)O[C@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)C)O)O)O)C)O)O)O)CO)O)O)O
|
| InChi Key |
UPROOJBJZLZCGS-CHTHVDMYSA-N
|
| InChi Code |
InChI=1S/C58H92O25/c1-23-11-16-58(53(73)83-51-44(71)40(67)37(64)30(79-51)22-75-48-45(72)41(68)46(29(20-59)78-48)81-49-42(69)38(65)34(61)24(2)76-49)18-17-56(7)26(27(58)19-23)9-10-32-55(6)14-13-33(54(4,5)31(55)12-15-57(32,56)8)80-52-47(36(63)28(60)21-74-52)82-50-43(70)39(66)35(62)25(3)77-50/h9,24-25,27-52,59-72H,1,10-22H2,2-8H3/t24-,25-,27-,28-,29+,30+,31-,32+,33-,34-,35-,36-,37+,38+,39+,40-,41+,42+,43+,44+,45+,46+,47+,48+,49-,50-,51-,52-,55-,56+,57+,58-/m0/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-4,5-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-6a,6b,9,9,12a-pentamethyl-2-methylidene-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~84.08 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8408 mL | 4.2040 mL | 8.4080 mL | |
| 5 mM | 0.1682 mL | 0.8408 mL | 1.6816 mL | |
| 10 mM | 0.0841 mL | 0.4204 mL | 0.8408 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
